Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Single-Arm, Phase 1/2 Dose-Escalation Trial of Long-Acting Recombinant Human IL-7 (NT-I7, Efineptakin-Alpha) for Idiopathic CD4 Lymphopenia

Next Previous
Trial Profile

An Open-Label, Single-Arm, Phase 1/2 Dose-Escalation Trial of Long-Acting Recombinant Human IL-7 (NT-I7, Efineptakin-Alpha) for Idiopathic CD4 Lymphopenia

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efineptakin alfa (Primary)
  • Indications Idiopathic CD4-positive T-lymphocytopenia
  • Focus Adverse reactions

Most Recent Events

  • 08 Nov 2024 Planned initiation date (estimated date for recruitment of the first subject) changed to 13 Nov 2024.
  • 29 Oct 2024 Planned initiation date (estimated date for recruitment of the first subject) changed from 31 Oct 2024 to 3 Nov 2024.
  • 28 Oct 2024 Planned initiation date changed from 29 Oct 2024 to 31 Oct 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top